Arlington Capital Partners Announces Majority Investment in Grand River Aseptic Manufacturing

WASHINGTON–(BUSINESS WIRE)–Arlington Capital Partners (“Arlington”), a Washington, DC-area private
equity firm, today announced a majority investment in Grand River
Aseptic Manufacturing (“GRAM” or the “Company”). Based in Grand Rapids,
MI, GRAM is a leading contract, development and manufacturing
organization (“CDMO”) focused on the development, manufacture and
finishing of parenteral pharmaceuticals. GRAM focuses on partnering with
its pharmaceutical and biopharmaceutical customers to provide full life
cycle aseptic solutions from development through commercialization.

Matt Altman, a Managing Partner at Arlington, said, “Arlington is
excited to partner with the GRAM team to continue building a world-class
aseptic CDMO. The Company’s broad manufacturing experience and exemplary
quality record provide an ideal platform from which to pursue the
numerous growth initiatives we have collectively identified within the
large and growing aseptic manufacturing market. Our investment in GRAM
continues Arlington’s history of building differentiated pharma services
providers in partnership with leading management teams.”

“With the healthcare network, strategic vision and capital that
Arlington brings to GRAM, we look forward to expanding our offerings and
better serving our growing client base,” commented Tom Ross, CEO of
GRAM. “Arlington has a strong track record of investing in
pharmaceutical services and shares our vision for expanding GRAM’s
capacity and capabilities with a focus on putting quality first.”

Malcolm Little, a Principal at Arlington, said, “The additional capacity
made available by Arlington’s investment will position GRAM to continue
capitalizing on the rising demand for parenteral development and
manufacturing services driven by growth in the underlying biologic and
generic injectables markets. Rising regulatory pressures and continued
consolidation have made independent aseptic manufacturing platforms,
like GRAM, increasingly scarce and valuable.”

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private equity
firm that has managed $2.2 billion of committed capital via four
investment funds, including Arlington’s fourth and most recent $700
million fund. Arlington is focused on middle market investment
opportunities in growth industries, including: healthcare,
aerospace/defense, government services and technology, and business
services and software. The firm’s professionals and network have a
unique combination of operating and private equity experience that
enable Arlington to be a value-added investor. Arlington invests in
companies in partnership with high quality management teams that are
motivated to establish and/or advance their Company’s position as
leading competitors in their field.

About Grand River Aseptic Manufacturing

Grand River Aseptic Manufacturing, a parenteral contract development and
manufacturing organization, delivers customized solutions to meet
clients’ fill and finish needs from development through
commercialization. With capabilities for biologics as well as controlled
substances, GRAM’s expert project managers and modern facilities support
pharmaceutical development and cGMP manufacturing, analytical testing
and regulatory filing.


Arlington Capital Partners
Matthew Altman
5425 Wisconsin
Avenue, Suite 200
Chevy Chase, MD 20815